Article
mRNA-encoded mutant HPV16/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice.
Journal for immunotherapy of cancer - 17 Sept 2025
Zhang Qiang, Cao Beibei, Li Lei, Zhou Ya, Ni Chenxing, Zhao Yongchao, Xu Dong, Yu Hongxiaoying, Jin Lushuai, Zhang Ying, Qiao Xue, Zhang Jianqi, Liu Shaoli, Zhang Xiaoju, Liu Andong, Han Hongya, Ma Xiaoyun, Xu Wei
Abstract excerpt
BACKGROUND: Persistent infection with high-risk human papillomavirus (HPV) 16 and 18 is a major driver of human cancer, including head and neck and cervical cancers. Although prophylactic vaccines prevent infection, effective therapies for established HPV-related cancers are needed. In this study, we developed a messenger RNA (mRNA)-based therapeutic vaccine encapsulated in lipid nanoparticles (LNP) encoding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.